论文部分内容阅读
目的:评价磷酸依米他韦胶囊分别与索磷布韦片、奥美拉唑镁肠溶片、瑞舒伐他汀钙片在健康受试者中的药物-药物相互作用及联合用药的耐受性。方法:试验1（磷酸依米他韦胶囊与索磷布韦片）采用随机、开放、连续给药设计，纳入28例受试者随机分为2组。试验2（磷酸依米他韦胶囊与奥美拉唑镁肠溶片）采用非随机、开放设计，纳入42例受试者分为3组。试验3（磷酸依米他韦胶囊与瑞舒伐他汀钙片）采用开放设计，纳入14例受试者。采用验证过的液相色谱串联质谱分析方法（LC-MS/MS）检测依米他韦、索磷布韦及其主要代谢产物GS-331007、奥美拉唑、瑞舒伐他汀的血药浓度，采用Phoenix WinNonlin软件计算药代动力学参数。结果:（1）试验1中，单药和联合给药后，索磷布韦Cn max和AUCn 0-tau几何平均值比值（GMR）的90% n CI为152.0%（118.0%～197.0%）和230.0%（184.0%～287.0%），与索磷布韦单药比较，分别增加了52.0%和130.0%；GS-331007 Cn max GMR的90% n CI为74.0%（67.5%～81.2%），与索磷布韦单药比较，降低了26.0%。（2）试验2中，同时给药、间隔4 h给药、间隔12 h给药，依米他韦单药和联合给药后Cn max GMR的90% n CI分别为68.9%（44.5%～106.7%）、64.0%（43.8%～93.6%）和56.4%（38.9%～81.9%）；AUCn 0-t GMR的90% n CI分别为68.6%（46.5%～101.2%）、68.3%（47.6%～98.0%）和60.5%（41.8%～87.5%），与依米他韦单药比较，Cn max和AUCn 0-t分别降低31.1%和31.4%、36.0%和31.7%、43.6%和39.5%。（3）试验3中，单药和联合给药后，瑞舒伐他汀Cn max和AUCn 0-72 GMR的90% n CI分别为172.4%（153.6%～193.5%）和158.0%（144.3%～172.9%），与瑞舒伐他汀单药比较，分别升高了72.4%和58.0%。试验期间均未发生严重不良事件和导致退出试验的不良事件。n 结论:磷酸依米他韦胶囊与索磷布韦片、奥美拉唑镁肠溶片、瑞舒伐他汀钙片均存在药物相互作用。“,”Objective:To evaluate the drug-drug interactions and the tolerability of combined medication between yimitasvir phosphate capsules with sofosbuvir tablets, omeprazole magnesium enteric-coated tablets, and rosuvastatin calcium tablets in healthy volunteers.Methods:A randomized, open, and continuous administration design was used in trial 1 (yimitasvir phosphate capsules with sofosbuvir tablets). 28 subjects were randomly divided into two groups. A non-randomized, open design was used in trial 2 (yimitasvir phosphate capsules with omeprazole magnesium enteric-coated tablets), and included 42 subjects divided into three groups. The open design method was used in trial 3 (yimitasvir phosphate capsules with rosuvastatin calcium tablets), and included 14 subjects. The plasma concentrations of yimitasvir phosphate, sofosbuvir and their main metabolites GS-331007, omeprazole and rosuvastatin were validated by a liquid chromatography/tandem mass spectrometry (LC-MS/MS). The pharmacokinetic parameters were calculated by Phoenix winNonlin software.Results:(1) in trial 1, after single and co-administration, the 90% n CI of sofosbuvir Cn max and AUCn 0-tau geometric mean ratio (GMR) were 152.0% (118.0% ~ 197.0%) and 230.0% (184.0% ~ 287.0%), with an increase of 52.0% and 130.0% compared to single dose of sofosbuvir, respectively. The 90% n CI of GS-331007 Cn max GMR was 74.0% (67.5% ~ 81.2%) and reduced by 26% compared to single dose of sofosbuvir. (2) in trial 2, the 90% n CI of Cn max GMR after yimitasvir single or co-administration at the same time, with a 4-hours interval, or with a 12- hours interval were 68.9% (44.5% ~ 106.7%) , 64.0% (43.8% ~ 93.6%) and 56.4%(38.9% ~ 81.9%), and the 90% n CI of AUCn 0-t GMR were 68.6% (46.5% ~ 101.2%), 68.3% (47.6% ~ 98.0%) and 60.5% (41.8% ~ 87.5%), respectively. Compared with single dose of yimitasvir, the Cn max and AUCn 0-t were decreased by 31.1% and 31.4%, 36.0% and 31.7%, 43.6% and 39.5%, respectively. (3) In trial 3, after single and co-administration, the 90% n CI of rosuvastatin Cn max and AUCn 0-72 GMR were 172.4% (153.6% ~ 193.5%) and 158.0% (144.3% ~ 172.9%), respectively, with an increase of 74.9% and 60.5% compared to single dose of rosuvastatin. There were no serious adverse events and adverse events leading to withdrawal from the trial.n Conclusion:Yimitasvir phosphate capsules have drug-drug interactions with sofosbuvir tablets, omeprazole magnesium enteric-coated tablets, and rosuvastatin calcium tablets.